BX 004
Alternative Names: BX-004; BX004-ALatest Information Update: 09 Nov 2025
At a glance
- Originator BiomX
- Class Antibacterials; Bacteriophages
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Yes - Pseudomonal infections
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pseudomonal infections
- Preclinical Bronchiectasis
Most Recent Events
- 17 Oct 2025 BiomX addresses the FDA’s queries related to the third-party nebulizer used to deliver BX004. An additional FDA request for limited technical clarifications on the nebulizer has been addressed
- 17 Oct 2025 BiomX plans a phase III trial for cystic fibrosis
- 19 Aug 2025 The US FDA issues a clinical hold on a phase IIb trial for BX 004 in Cystic fibrosis (CF), with no mention of safety or efficacy concerns related to the BX 004